Navigation Links
NYU scientists identify critical protein complex in formation of cell cilia
Date:8/19/2008

NEW YORK, August 19, 2008 An international team led by NYU Cancer Institute have identified a protein complex that regulates the formation of cilia, which are found on virtually all mature human cells and are essential to normal cell function.

The new report, published this week by Developmental Cell and selected as the featured publication of the open-access online edition, describes how three proteins work together to regulate the formation of primary cilia. The study led by Brian Dynlacht, Ph.D., professor of pathology and director of NYU Cancer Institute Genomics Facility, investigates these antenna-like structures, once thought to be vestigial remnants of cell evolution, which have recently emerged as a focal point of research in developmental cell biology.

"We are trying to understand the regulation of processes that are fundamental to normal cell development and health in humans," said William Y. Tsang, Ph.D., of the NYU School of Medicine and Cancer Institute, and first author of the paper. "Defective cilia are implicated in a wide range of serious illnesses such as polycystic kidney disease, retinal degeneration, and neurological disorders. Inappropriate activation of signaling molecules that normally reside at the primary cilium, may lead to certain cancers."

At the center of the process lies the protein CEP290, which normally promotes primary cilia formation in mature cells. Dr. Tsang and his colleagues discovered that a second protein, CP110, normally suppresses the function of CEP290 until cells are fully mature. At that point, CP110 is destroyed, freeing CEP290 to interact with a third protein, Rab8a, to promote cilia formation on the surface of the mature cell.

The team's findings may help to identify potential targets for future drug design.

"Ciliogenesis is a fundamental process. These structures are found in almost every type of human cell you can imagine," Dr. Tsang said. "If we can ever design drugs that will restore the formation and function of cilia even in the presence of CEP290 mutations, then that would be one way to cure the defects that lead to ciliary diseases."

Research so far has been using in vitro human cell lines. However, team members from the University of Michigan and National Eye Institute have developed a mouse model with a CEP290 mutation implicated in retinal degeneration, and the NYU group is planning a study of human CEP290 mutations to see if they can correlate genotypes to their expression in specific ciliary diseases.


'/>"/>

Contact: Jennifer Berman
Jennifer.Berman@nyumc.org
212-404-3555
NYU Langone Medical Center / New York University School of Medicine
Source:Eurekalert

Related biology news :

1. Johns Hopkins scientists discover what drives the development of a fatal form of malaria
2. Smithsonian scientists discover new bird species
3. Scientists discover major genetic cause of colorectal cancer
4. Scientists overcome nanotech hurdle
5. Strange molecule in the sky cleans acid rain, scientists discover
6. Scientists team up in Houston to tackle global challenges
7. Scientists find elephant memories may hold key to survival
8. Scientists to assess Beijing Olympics air pollution control efforts
9. Scripps scientists will assess Beijing Olympics air pollution control efforts
10. Midge-hunting scientists tackle spread of devastating bluetongue virus
11. Scientists a step closer to producing fuel from bacteria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/5/2017)... 2017 KEY FINDINGS The global ... a CAGR of 25.76% during the forecast period of ... factor for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is ... geography. The stem cell market of the product is ...
(Date:3/30/2017)... March 30, 2017  On April 6-7, 2017, Sequencing.com ... Genome hackathon at Microsoft,s headquarters in ... will focus on developing health and wellness apps that ... Hack the Genome is the first hackathon for ... world,s largest companies in the genomics, tech and health ...
(Date:3/29/2017)...  higi, the health IT company that operates the ... , today announced a Series B investment from ... The new investment and acquisition accelerates higi,s strategy to ... population health activities through the collection and workflow integration ... collects and secures data today on behalf of over ...
Breaking Biology News(10 mins):
(Date:7/20/2017)... ... 2017 , ... Litmus Health , a clinical data ... board. The board comprises leaders spanning business, technology, academia, and pharmaceutical research. The ... Engineering, to Chief Technology Officer. Crooks will lead strategy and development of the ...
(Date:7/20/2017)... and PLYMOUTH, Minn., July 20, 2017   KCNQ2 ... personalized genetic evaluations company, today announced that they ... investigating a genetic mutation implicated in KCNQ2 epileptic ... partnership for a second case involving an additional ... KCNQ2 Cure Alliance and Pairnomix entered into a ...
(Date:7/18/2017)... ... July 18, 2017 , ... ... and biotherapeutics development, announces the launch of a new NTA biosensor chip for ... researchers to study the kinetics of polyhistidine-tagged (His-tagged) molecules quickly and reliably. ...
(Date:7/18/2017)... ... 18, 2017 , ... G-CON today announced that it has ... its Patent Applications 14/858,857 and 13/669,785 both entitled Modular, Self-Contained, Mobile Clean Room. ... the protection of G-CON’s R&D investments and validate the G-CON platform as a ...
Breaking Biology Technology: